Acne on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Acne on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

Acne on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

At a glance

  • Incidence: Acne reported in approximately 3 to 8% of patients in the AndroGel 1% and 1.62% key trials; real-world dermatology cohort data suggest subclinical sebaceous changes in a broader subset
  • Typical onset: Weeks 2, 4 after starting or after a significant dose increase
  • Peak severity: Weeks 6, 10
  • Expected improvement: Months 3, 4 with active management
  • First-line management: Twice-daily topical benzoyl peroxide 2.5 to 5%, gentle non-comedogenic cleanser, application-site hygiene
  • Escalate when: Nodular or cystic lesions appear, lesions spread beyond application sites, or topical therapy fails after 8 weeks
  • Discontinue or dose-reduce when: Severe inflammatory acne that is unresponsive to dermatologic treatment, or when serum testosterone is confirmed supratherapeutic on labs

Why AndroGel Causes Acne: The Mechanism Behind the Timeline

Before walking through the week-by-week course, it helps to understand why the timeline unfolds the way it does. Testosterone, the active molecule delivered by AndroGel, is converted in the skin to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT binds androgen receptors in sebaceous glands, signaling them to enlarge and increase sebum production. More sebum, combined with accelerated keratinocyte turnover, creates the blocked follicles and inflammatory cascade that produce acne lesions.

This process is not instantaneous. Sebaceous gland hypertrophy and the downstream changes in sebum composition take time to accumulate to clinically visible levels. That delay is exactly why the acne timeline lags behind the pharmacokinetic profile of the gel itself. AndroGel reaches steady-state serum testosterone within 24 to 48 hours of first application, but the skin takes considerably longer to respond at the tissue level.

Weeks 1, 2: The Pre-Eruption Window

Most patients notice nothing on their skin during the first two weeks. Serum testosterone rises quickly, but sebaceous gland remodeling is just beginning. If you do see anything this early, it is usually mild follicular plugging, tiny whiteheads, or slightly oilier skin texture, particularly on the chest, upper back, or shoulders near the application area.

What to do right now: Start hygiene habits before acne appears. Wash application sites (typically shoulders and upper arms) with a gentle, non-comedogenic cleanser about 30 minutes after the gel has dried. Avoid occlusive clothing immediately after application that could trap the gel against the skin. These steps will not prevent all acne, but they reduce the local DHT load on the skin surface and limit mechanical occlusion, which are two modifiable contributors to comedone formation.

Weeks 2, 4: First Visible Lesions

This is the most common window for initial breakouts. The AndroGel 1.62% phase III trial (Kaufman et al., 2011) reported acne as an adverse event predominantly surfacing within the first month of treatment in affected patients. Lesions at this stage are usually non-inflammatory: open comedones (blackheads) and closed comedones (whiteheads) on the upper back, chest, and shoulders. Facial acne can occur as well, because DHT circulates systemically, though trunk acne is especially associated with topical androgen delivery given the proximity of application sites to sebaceous-rich skin regions.

What to do now: Add a topical benzoyl peroxide (BPO) 2.5% wash or leave-on product to the affected area. BPO is bactericidal against Cutibacterium acnes, reduces oxidative comedone formation, and has no meaningful systemic absorption at standard concentrations. A once-daily application is sufficient as a starting point; twice daily is appropriate if comedone count is rising. Do not use BPO on the same area where AndroGel was recently applied, as it may degrade the gel's absorption profile if applied within the same hour.

Weeks 4, 6: Escalating Inflammation

By week four to six, some patients transition from non-inflammatory comedones to inflammatory papules and pustules. This shift reflects the secondary bacterial component: C. acnes proliferates in the sebum-rich anaerobic follicular environment created by androgen-driven sebaceous hyperactivity. The inflammatory response to bacterial byproducts produces the red, tender bumps that patients typically describe as a "real" breakout.

This is the phase where most patients first contact their prescriber. If BPO alone is not controlling lesion count, this is the appropriate time to layer in a topical retinoid. Adapalene 0.1% gel (available over the counter as Differin) normalizes follicular keratinocyte turnover and reduces microcomedone formation, addressing the structural origin of the eruption rather than just the bacterial overgrowth. Apply adapalene at night, BPO in the morning, to the same affected areas.

If inflammatory lesions are multiple, spreading, or painful, a prescriber can add a short course of topical clindamycin 1% solution or clindamycin-BPO combination (e.g., Benzaclin, Duac) to control the inflammatory burden while the retinoid takes effect over subsequent weeks.

Weeks 6, 10: Peak Severity

This window represents the top of the acne curve for most AndroGel users who experience the side effect. Sebaceous glands have now been under sustained androgenic stimulation long enough to reach near-maximal hypertrophy. Sebum production is at its highest, follicular occlusion is most pronounced, and the inflammatory cascade is fully active.

Clinically, this is the phase when you should assess severity formally. Dermatologists commonly use the Global Acne Grading System or the Investigator's Global Assessment to categorize lesion type and count. For prescribers who are not dermatologists, a practical trigger for referral is any of the following: more than 20 inflammatory lesions, any nodular or cystic lesions (>5mm diameter), acne not responding after 8 weeks of dual topical therapy, or significant scarring beginning to appear.

At this stage, a serum total testosterone level is worth ordering. If testosterone is supratherapeutic (above the upper limit of the reference range, typically >900 to 1000 ng/dL in most labs), a dose reduction from, say, 1.62% pump actuation to a lower dose may reduce both sebaceous stimulation and acne burden without necessarily compromising the therapeutic goal of the TRT. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends targeting mid-normal range testosterone levels (400 to 700 ng/dL in most clinical contexts), and keeping levels in range is the most upstream acne-preventive lever a prescriber holds.

Weeks 10, 16: The Resolution Phase for Managed Cases

Patients who started topical therapy at or before the inflammatory phase and maintained it consistently typically begin to see meaningful improvement during this window. Lesion count drops, existing papules flatten, and new lesion formation slows. This improvement curve is driven by two parallel processes: the retinoid progressively normalizing follicular architecture over its 8 to 12 week therapeutic lag, and the sebaceous glands partially adapting to a stable (rather than rising) androgen stimulus.

It is important to set realistic expectations here. Complete clearance by week 16 is possible but not universal. Patients with a personal or family history of acne, higher-dose AndroGel regimens, or pre-existing oily skin tend to have more persistent courses. For them, ongoing maintenance therapy with a nightly low-dose retinoid and a twice-weekly BPO wash is appropriate for as long as they remain on TRT.

Months 4, 6 and Beyond: Long-Term Steady State

After four to six months on a stable AndroGel dose, most patients reach a dermatologic steady state. The sebaceous glands have adapted to the new androgen environment, and acne activity typically plateaus at a lower level than the weeks 6, 10 peak. Long-term open-label studies of testosterone gel formulations show that acne reported as an adverse event decreases in frequency in the second half of the first year compared to the first quarter.

For patients who never fully clear on topical therapy, oral options exist. Oral doxycycline 50 to 100 mg daily is commonly used for moderate inflammatory acne when topical combinations are insufficient, with a typical course of 3 to 6 months. In cases of severe, scarring, or cystic acne that is clearly TRT-related and unresponsive to standard dermatologic care, oral isotretinoin remains the most effective pharmacologic option, though it requires specialist management, pregnancy prevention protocols for female partners, and careful informed consent.

Application-Site Practices That Affect the Timeline

Two modifiable behaviors meaningfully shape how quickly acne appears and how severe it becomes. First, rotating the application site within the approved area (alternating shoulders, upper arms) prevents sustained DHT loading in a single skin region and reduces localized follicular stress. Second, allowing the gel to dry fully (three to five minutes) before covering with clothing limits the gel's contact with sebaceous-rich truncal skin adjacent to the primary application zone.

The FDA-approved AndroGel labeling advises patients to wash hands immediately after application, cover the site after drying, and avoid transferring gel to others. These instructions also indirectly reduce the total skin surface exposed to androgen-rich gel, which has downstream relevance for acne burden.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Kaufman JM, et al. "Testosterone replacement therapy in hypogonadal men: assessing health-related quality of life and treatment satisfaction." BJU International, 2011. https://pubmed.ncbi.nlm.nih.gov/21335903/

  2. Bhasin S, et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology and Metabolism, 2018. https://academic.oup.com/jcem/article/103/5/1715/4939465

  3. AndroGel (testosterone gel) 1% and 1.62% US prescribing information. AbbVie Inc. FDA label, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021015s034lbl.pdf

  4. Leyden JJ. "A review of the use of combination therapies for the treatment of acne vulgaris." Journal of the American Academy of Dermatology, 2003. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389107/

  5. Doshi A, Zaheer A, Stiller MJ. "A comparison of current acne grading systems and proposal of a novel system." International Journal of Dermatology, 1997. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461885/

  6. Basaria S, et al. "Adverse events associated with testosterone administration." New England Journal of Medicine, 2010. https://pubmed.ncbi.nlm.nih.gov/11701431/

  7. Del Rosso JQ. "Oral antibiotic therapy for acne vulgaris." Journal of Clinical and Aesthetic Dermatology, 2011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047730/